Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b double-blind randomized placebo-controlled study of bimagrumab and tirzepatide alone or in combination in overweight or obese adults with type 2 diabetes mellitus
CTR20251996Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bimagrumab, tirzepatide in type 2 diabetes mellitus (T2DM), obesity, Overweight, sponsored by Eli Lilly and Company. Started May 2025; status: terminated.
02
Drugs
bimagrumabtirzepatide
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on CTR20251996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251996.